ORPHYRIAS ARE A group of inherited disorders caused by specific defects along the heme biosynthetic pathway. Congenital erythropoietic porphyria (CEP) or Gunther's disease is a rare disease that is inherited as an autosomal recessive trait. CEP is characterized by severe cutaneous photosensitivity, chronic hemolysis, and massive porphyrinuria resulting from the accumulation in the bone marrow, peripheral blood, and other organs of large amounts of predominantly type I porphyrins, which are not substrates for heme synthesis.' A characteristic abnormality of the disease is a 80% to 98% decrease in the activity of uroporphyrinogen I11 synthase (UROIIIS), the fourth enzyme of the heme biosynthetic
The determination of the nucleotide sequence of the cDNA encoding UROIIIS4 has made possible the study of the molecular lesions responsible for the disease,'" permitting the detection of heterozygotes and their counselling, as well as facilitating genotype-phenotype correlations for this disease.
The prognosis of CEP is poor with death in early adult life and available treatments are unsatisfactory. Because the enzyme defect occurs in bone marrow normoblasts, bone marrow transplantation represents a curative treatment for patients with severe phenotypes. Because HLA-identical donors are rarely available, somatic gene therapy might be an effective alternative therapeutic strategy. The use of retroviral vectors to insert genes into hematopoietic cells has been investigated extensively in animal models8 and most recently in To explore gene transfer for the treatment of CEP, we constructed a retroviral transduction system based on the LXSN vector" and containing the full-length UROI-IIS cDNA. Gene transfer into deficient Epstein-Barr virus (EBV)-transformed B-cell (or lymphoblastoid cell) lines (LB-) restored UROIIIS enzyme activity. Furthermore, porphyrin accumulation into the deficient transduced cells was reduced to the normal level, demonstrating the metabolic correction of the disease.
P

MATERIALS AND METHODS
Cell lines. Lymphoblastoid cell lines established from peripheral blood lymphocytes after EBV transformation of normal individuals (LBN) and patients with CEP (LB-) were obtained from Genethon (Evry, France Barr virus-transformed B-cell lines from patients with CEP provide a model system for the disease. We have used retrovirus-mediated expression of UROlllS to restore enzymatic activity in a B-cell line from a patient. We have also demonstrated the metabolic correction of the disease, ie, porphyrin accumulation into the deficient transduced cells was reduced to the normal level. These data show the potential of gene therapy for this disease. 0 7995 by The American Society of Hematology. tained at 0.5 to 2 X IO6 cellslmL in RPMI 1640 supplemented with 15% fetal calf serum (FCS), 100 U/mL of penicillin, and 1 mg/mL of streptomycin (GIBCO BRL, Grand Island, NY) at 37°C in a 5% CO, atmosphere. The packaging cell lines (LCRE and (LCRIP (kindly provided by 0. Danos and J.M. Heard, Institut Pasteur, Paris, France) were maintained in RPMI 1640 supplemented with 10% newborn calf serum and antibiotics.
Construction and packaging of retroviral vector LUSN. A fulllength UROIIIS cDNA was isolated from the pKK 223-US plasmid6 and inserted into EcoRI-BamHI linearized retrovirus vector pLXSN" to get pLUSN (Fig 1) . pLUSN was then transfected by calciumphosphate precipitation into the ecotropic packaging cell line (LCRE.
Filtered supernatants from ecotropic virus-producing cells were then added to the amphotropic cell line (LCRIP in the presence of 8 pg/ mL polybrene (Sigma, Saint Quentin, France). (3418-(Geneticin; GIBCO BRL) resistant clones were isolated and screened for those producing the highest titer using NIH3T3 cells as targets. The best clone was used for further studies (IO6 particles/mL). The supernatant was tested for the presence of replication competent virus.
Transduction of target cells. The lymphoblastoid cell line (C73m228M) was transduced either by cocultivation or by retroviral supernatant infection. By cocultivation, the retroviral producer cell lines (LCRIPLUSN and (LCRIPLXSN were seeded at lo6 cells/ IO-cm dish (30% to 40% confluency) the day before transduction. The following day, medium from producer cells were replaced by RPMI 1640 medium supplemented with 15% FCS containing 2 X lo6 lymphoblastoid cells and 8 pg/mL polybrene. The producer cell line and target cells were cocultivated for 48 hours. The unattached lymphoblastoid cells were transferred to another dish and maintained without selection for 2 weeks to allow expansion. Adherent cells were removed by replating. LB were subjected to an initial period The vector also contains the neomycin phosphotransferase gene (Neon) driven by the SV40 eady promoter (SV40 epl as well as t h e origin of replication (ori) and ampicillin resistance gene (amp) from PBR 322 for bacterial growth.
of selection in 0.4 mg/mL G418 for 2 weeks and then maintained in medium containing 1 mg/mL G418 for 10 weeks.
For retroviral supernatant infection, 4 mL of the filtered supernatant obtained from producer cells was added to the 2 X IO6 target cells in the presence of 8 pg/mL polybrene during 3 hours for 6 consecutive days (2: 1 colony-forming unitdcell ratio). Selection was performed as described above.
Southern blot analysis. High molecular weight DNA was extracted from lymphoblastoid cells by the usual methods and analyzed by gel blot hybridization. Ten micrograms of genomic DNA was digested with Sad; this enzyme cuts in both LTR regions in our construct and produces a 3.6-kb band from the LUSN vector ( Fig  2) . The resulting fragments were separated on a 1% agarose gel and transferred onto nylon membrane (Hybond N"; Amersham, Les Ulis, France). Known amounts of digested plasmid DNA (20, 10, and 5 pg) mixed with control LB DNA (10 pg) were run on the same gel. Filters were hybridized with a 780-bp human UROIIIS cDNA fragment that was labeled with [32P]dCTP by random priming (Multiprime DNA labeling system; Amersham). The vector copy number per genome was estimated by comparison of the amount of radioactivity (Phosphor Imager; Molecular Dynamics, Sunnyvale, CA). The radioactivity obtained with 10 pg of plasmid DNA corresponds to the presence of one copy of the human genome when 10 pg of genomic DNA is used for the blot.
Determination of UROIIIS enzyme acfivify. A total of 1 6 to IO6 LB cells (depending on the specific enzymatic activity) were microfuged for 30 seconds and the pellets were washed with phosphate-buffered saline (PBS). The cells were resuspended in 250 pL of UROlIlS lysis buffer ( 1 0 0 mmoVL Tris-Cl, pH 8.0, containing 1 mmol/L EDTA and 1 % Tween-20). disrupted by sonication on ice, and microfuged for 5 minutes. Supernatants were assayed for UROI-IIS activity as described elsewhere." One unit of UROllIS activity was defined as the amount of enzyme that formed 1 nanomole of uroporphyrinogen III per hour at 37°C.
Porphyrin accumulation in lymphoblasroid cells and in the medium. Experiments were performed in polystyrene multiwell trays seeded with 5 X l 6 celIs/well. LB were exposed to 0.3 mmol/L and 0.6 mmoVL 6 aminolevulinic acid (ALA; Sigma) for 24 and 48 hours. The medium was then kept, the cells were washed with PBS, and the porphyrins were extracted from the cells and the culture medium with 1 moVL HC10JCH30H (1:l. vol/vol). The total porphyrin concentrations of the extracts were determined by spectrofluorimetry (excitation, 404 nm; emission, 595 nm) using an uroporphyrin I standard solution (10 nmol/L). The porphyrins accumulated in the cells and in the medium were identified after separation by high performance liquid chromatography (HPLC)." Uroporphyrin isomers were also separated by C18 reversed HPLC."
RESULTS
Transduction of target cells. Lymphoblastoid cell lines from patients with CEP were transduced with LXSN (control virus) and LUSN particles at a multiplicity of infection (MOI) of 2:l.
A Southern blot analysis showed that LB-deficient cell lines transduced with LUSN and selected by G418 carried 1 copy per genome. We observed the same gene transfer efficiency for the cells transduced by cocultivation and for those transduced by retroviral filtered supernatant (Fig 2) .
UROIIIS activity in n o m 1 cells as well as in transduced and nontransduced deficient cell lines. LBN, nontransduced LB-, and transduced LB-cells were collected before and after G41 8 Porphyrin acx:urnulation. To evaluatc the ability of LUSN transduction to correct the metabolic defect, the protile of porphyrin accutnulation was first studied in normal and deficient LB cells in the presence or absence of ALA, the natural precursor of tetrapyrrole biosynthesis. I n the normal cell lines studied, a very low amount of porphyrin could be found when they were incubated in the absence of ALA. The level of porphyrin generated by normal cells in the presence of ALA was also very low and identified to be mostly protoporphyrin IX. In the case of deficient cells, a significant amount of porphyrin was even found in the absence of ALA (4 to 8 ftnol/lO' cells). When the two different deficient LB cell lines were incubated with ALA for 24 and 48 hours at concentrations of 0.3 and 0.6 mmol/L, the level of accumulated porphyrins was very high (from 28 to 175 fmol/103 cells for the different conditions; Fig 3) . These porphyrins were identified after separation by HPLC a s uroporphyrin l (80%) and coproporphyrin I (20%).
Under these conditions, porphyrin accumulation provided an indirect estimation of UROIIIS activity. The highest ratio of porphyrin accumulation between normal and deficient cells was found when cells were incubated with 0.3 m r n o l / L ALA; these conditions were kept for further studies. LBdeficient cells transduced by LUSN, selected by G41 X, and then exposed for 24 and 48 hours to 0.3 mmol/L ALA displayed very low levels of porphyrin accumulation, similar to the level obtained with normal cells (respectively, I O -and 15-fold lower than for the same nontransduced cells). This result showed that the transduction of deficient cells by ISJSN corrected the porphyric phenotype.
To determine the ability of normal LB and transduced deficient LB cells L o effect 21 metabolic cross-correction of nontransduced deficient LB cells, normal LB and transduced deficient cells were cocultured for 24 hours with a variable percentage of nontransduced deficient LB cells. Porphyrin accumulation was then studied as described above. The level o f porphyrin accumulation i n coculturcd cells corresponded closely to that expected f~-om the proportion of the different cells studied (Fig 4) . Uroporphyrinogen I I l + Coproporphyrinogen III been described include hypertransfusion, splenectomy, the administration of haematin, oral activated charcoal, hydroxyurea, and low doses of c h l~r o q u i n e .~~"~ A single patient has been treated by bone marrow transplantation from an HLAidentical sibling." There was a remarkable amelioration of the porphyria, but the patient died 11 months later from cytomegalovirus infection. Gene therapy by retrovirus-mediated insertion of the normal UROIIIS gene into hematopoietic cells seems to be an appropriate treatment of the disease in the future. We constructed a recombinant retroviral vector LUSN to mediate insertion and expression of human UROI-IIS cDNA in a lymphopoietic target cell population. Lymphoblastoid cell lines from a patient with CEP were targeted for LUSN transduction.
A full restoration of enzymatic activity was found in transduced and G418-selected deficient cells. Also, a complete metabolic correction of the porphyric phenotype was accomplished, as indicated by a total reversion of porphyrin accumulation in the cells. Because we know that the efficiency of retroviral transduction of hematopoietic cells in vitro and in vivo is low, we wanted to look at the possibility of metabolic cross-correction between nontransduced and transduced deficient or normal cell lines. This metabolic correction in neighboring nontransduced cells is well-established for human lysosomal storage diseases such as mucopolysaccharidosis type I1 (Hunter syndrome18) or type VI1 (Sly disease"). Our experiments show the absence of cross-correction between nontransduced and transduced cells. This result is not surprising because we could expect an absence of transfer of the enzyme from one cell to the other and also because uroporphyrin I and coproporphyrin I, which are the accumulated porphyrins, correspond to a metabolic deadend (Fig 5) . Except for the case of a selective advantage of corrected cells, these results suggest that gene replacement need to be performed on a high percentage of cells for a substantial improvement of the biochemical abnormalities and a subsequent amelioration of the clinical manifestations. Because the accumulation of porphyrins predominates in the erythropoietic lineage, the ideal target cell for gene therapy of CEP should be the myeloid stem cell or the pluripotent stem cell for long-term therapy. Recent studies using stromal cell support or cytokines have shown an enhanced efficiency of viral gene transfer (including retrovirus and adeno-associated virus) into such cell populations selected for expression of the CD34 antigen and thus enriched for the reconstituting stem cell More studies with other enhancers (ie, the locus control region) and the use of hematopoietic progenitor cells are required for the achievement of high expression of the UROIIIS cDNA in the erythropoietic lineage. However, we have documented sufficient gene transfer rate and metabolic correction in lymphopoietic cell lines to indicate that CEP should be a good candidate for treatment by gene therapy of hematopoietic stem cells.
